AI Kidney prognosis tech receives FDA approval

Plus earnings and asset sales have theses stocks soaring 🦅                                                                                                                                                                                                                                                                                                                                                                                                                 *together with Genprex (Nasdaq: GNPX)  Happy Friday, 360! As usual, here are our top investing ideas for today’s edition – and[Â]([check out the 4th of July](🇺🇲[specials on ALL of our incredible trading services](. Be the best prepared trader on the Street! RNLX - Up over 38% in pre-market after receiving FDA De Novo marketing authorization for its Kidney prognostic test ACCD - Up over 13% in pre after beating earnings and revenue estimates and increasing guidance BHG - Up over 30% in pre after selling its California Medicare Advantage business, Brand New Day and Central Health Plan for $600 million *A message on behalf of Sica Media 📈 Technical Trade Alert 📈 Genprex (Nasdaq: GNPX) We brought GNPX to your attention several weeks ago. The stock made a very nice move up at that time, but slipped over the last few weeks. Right now, it is an excellent time to get GNPX back on your radar 📈 The reason is that yesterday, GNPX issued what I thought was [BOMBSHELL news](💣, and I don’t think the market fully understood what it was all about. This small pharmaceutical company said that it was granted “fast-track designation” by the FDA for its small-cell lung cancer drug candidate, REQORSA. Jason Kolbert, Director of Research at Dawson James, certainly has taken notice. [He slapped a]([price target](on GNPX that is over 260% higher than current price levels. So see for yourself what all the buzz is about! Of course, always do your own research and make sure you are comfortable with the risks when it comes to any stock you decide to trade. No matter what… make sure you are keeping a close eye on GNPX today 👀 *sponsored by Sica Media, please see disclosures below RNLX - Up over 38% in pre-market after receiving FDA De Novo marketing authorization for its Kidney prognostic test Renalytix (RNLX) develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. Late Thursday evening,[the company announced]( the FDA had granted De Novo marketing authorization for RNLX’s KidneyIntelX.dkd prognostic test, to assess the risk of progressive kidney function decline in adults with Diabetes and early-stage Kidney disease. RNLX[stated that](: This affirms KidneyIntelX as a first-in-class, artificial intelligence enabled prognostic testing platform to guide care management for adults with type 2 diabetes and early-stage chronic (diabetic) kidney disease. Renalytix believes FDA authorization will lead to increasing test adoption, informing clinical guidelines, expanding insurance coverage, and pursuing additional international regulatory approvals. HC Wainwright & Co. reiterated its Buy on Renalytix, maintaining its $5 price target. $2.85 has acted as support so far in the pre-market and should be an important level to watch. Above it, targets to the upside are $3, $3.20, $3.40 and then the pre-market high of $3.72. Beyond that, $3.92, $4.20, $4.60 and $5 come into play. Below $2.85, there is potential support at $2.60, $2.40 and a gap to fill at $2.07. ACCD - Up over 13% in pre after beating earnings and revenue estimates and increasing guidance Accolade (ACCD) engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers and virtual primary care physicians. The company [released Q1 earnings]( in the after-hours yesterday, reporting Q1 EPS of -$0.52 vs -$0.62 analyst estimate. Revenue came in at $93.2 million vs the $90.27 million consensus. ACCD also guided Q2 2024 revenue of $93-$95 million vs the $93 million consensus. It also sees FY 2024 revenue of $410-$414 million vs the $410 million consensus. The stock is up over 13% on the earnings beat. The $14 area has been support in the after-hours and pre-market. Above it, targets to the upside are $14.50, and then the pre-market high of $15. Beyond that, there is a gap to fill at $16 and then $17 with $19 above that. Below $14, there is potential support at $13.70, $13.20 and then a gap to fill at $12.64. BHG - Up over 30% in pre after selling its California Medicare Advantage business, Brand New Day and Central Health Plan for $600 million Bright Health Group (BHG) is a healthcare company, provides health insurance policies in the United States. This morning the company [announced the sale of its Medicare Advantage business](, Brand New DAY and Central Health Plan to Molina Healthcare for $600 million. [The company stated](: Upon closing, the proceeds of the sale will significantly strengthen Bright Health’s capital position. The Company intends to use the proceeds to satisfy its obligations to its bank lenders with the remaining proceeds used towards liabilities in its discontinued ACA insurance business. Bright Health is also announcing that it has extended a waiver and amendment to its credit facility. The stock is up 30% on the news in pre-market. According to Finviz, the company’s market capitalization at yesterday’s close was just $83.1 million. $13 was support in the pre-market and will be an important level to watch this morning. Above it, targets to the upside are $14, $14, 16, $16.74 and $17.90 above that. Beyond that, $20 and $22 come into play. Below $13, there is potential support at $12 and a gap to fill at $10.92. [Economic Calendar]( To Your Success! *please see disclosures below Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull - Refund Policy - Privacy Policy - Terms & Conditions *PAID ADVERTISEMENT. RagingBull has been paid ten thousand dollars by ach bank transfer by Lifewater Media for advertising Genprex Inc. from a period beginning on June 1, 2023 through June 1 of the same year. RagingBull has subsequently been paid fourteen thousand dollars by ach bank transfer by Sica Media for advertising Genprex Inc. from a period beginning on June 2, 2023 through June 2, seven thousand five hundred dollars by ach bank transfer by Sica Media for advertising Genprex Inc. from a period beginning on June 29, 2023 through June 29, and then seven thousand five hundred dollars by ach bank transfer by Sica Media for advertising Genprex Inc. from a period beginning on June 30, 2023 through June 30 of the same year. RagingBull has been paid a total of thirty eight thousand dollars to date for advertising related to Genprex. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of Raging Bull, do not hold a position in Genprex Inc. This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Genprex Inc., increased trading volume, and possibly an increased share price of the Genprex Inc. securities, which may or may not be temporary and decrease once the marketing arrangement has ended. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull can guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https:// www .sec. gov/edgar/searchedgar/companysearch TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. WE MAY HOLD SECURITIES DISCUSSED. [Ragingbull.com](, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 360wallstreet 62 Calef Hwy. #233 Lee, NH 03861, United States